NOVEMBER SALE - 20% OFF Everything!Shop Now
GLP-TZ Peptide
99.76% HPLC purityLot-tested · COA below

GLP-TZ Peptide

$126.00each · 20mg / Vial

4.7· 3 reviewsout of 5Out of stock

GLP-TZ, a dual GIP and GLP-1 receptor agonist peptide, in 10 mg and 20 mg research vials. 99.76% purity on the current lot, public COA, ships from the US.

Size

Regular price $158.00Sale price $126.00You save $32.00 (20%)

Out of stock

Enter your email and we'll let you know when this size is back.

U.S. delivery availableFree shipping on orders over $150.00
Reship policyWrong item sent? We reship it free. Transit issues reviewed case by case.

Secure checkout · Visa · Mastercard · American Express · Discover · PayPal · Venmo · Apple Pay

Test results · tested sample

99.76%

Reported purity · Tested by Bioviridian

Tested
Sep 25, 2026
Labeled
10mg / Vial
Lab
Bioviridian
View certificate (PDF) →

Product details

GLP-TZ, in brief. GLP-TZ is a single synthetic peptide that switches on two different gut hormone receptors at once: the GIP receptor and the GLP-1 receptor. Those two receptors normally answer to two separate hormones released from the gut after a meal, and both of them push the pancreas to release insulin only when glucose is already high. The reason for building one molecule that reaches both is to ask what the GIP arm adds on top of the GLP-1 arm, a question that is awkward to answer when two separate molecules are given together. In cell assays GLP-TZ behaves much like native GIP at the GIP receptor, and more weakly at the GLP-1 receptor, where it favours cAMP signalling over the arrestin route. In obese mice it lowered food intake and body weight, and raised insulin sensitivity further than a GLP-1 receptor agonist did at matched weight loss. The molecule itself is a 39-residue chain carrying a long fatty diacid that binds albumin, which is what slows its clearance. NextGenPeps supplies GLP-TZ as a lyophilised research material in 10 mg and 20 mg vials for laboratory use only.

What does GLP-TZ do?

It turns on two incretin receptors with one molecule. Incretins are hormones the gut releases when food arrives, and their job is to tell the pancreas that glucose is on the way. Two of them matter here: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Each has its own receptor. GLP-TZ binds both, which is why it is classed as a dual incretin receptor agonist rather than a GLP-1 receptor agonist.[1,2]

In practice that means three things:

  • At the GIP receptor, it behaves like the native hormone: a full agonist, with binding affinity and cAMP potency close to GIP itself.[1,2]

  • At the GLP-1 receptor, it is weaker than native GLP-1 and biased: strong on cAMP, very weak at recruiting beta-arrestin, and it drives much less receptor internalisation.[2]

  • In rodents, that combination lowers food intake, lowers body weight and raises insulin sensitivity, and part of the insulin sensitivity gain can be traced to the GIP arm on its own.[1,3]

NextGenPeps supplies GLP-TZ for in vitro research and approved animal studies only. It is not sold as a drug, supplement or diagnostic.

How does GLP-TZ work?

Both targets are class B G-protein-coupled receptors that couple to Gs. Agonist binding raises cAMP inside the cell, and in a pancreatic beta cell that rise amplifies insulin release when glucose is already elevated. Because the amplification depends on glucose, neither receptor drives insulin secretion on its own in a low-glucose state.[1,6] The GLP-1 arm also reaches feeding circuits: in rodents, GLP-1 receptor agonists act on hindbrain and hypothalamic sites reached through circumventricular organs rather than by crossing the blood-brain barrier generally.[8]

Figure 1. How GLP-TZ signals through two receptors.

Diagram showing GLP-TZ acting on the GIP receptor as a full agonist with affinity close to native GIP, and more weakly on the GLP-1 receptor at about five times lower affinity than native GLP-1, with downstream effects in adipose tissue, pancreatic islets, and brain and gut.

GLP-TZ engages the GIP receptor with affinity close to the native hormone and the GLP-1 receptor about five times more weakly, feeding into adipose tissue, pancreatic islet and brain and gut responses.[1,2,3]

The two halves of the molecule are not matched, and the numbers show it. In cells expressing the human receptors, GLP-TZ bound the GIP receptor with a Ki of 0.135 nM and raised cAMP with an EC50 of 0.0224 nM, both close to native GIP. At the GLP-1 receptor it was weaker, with a Ki of 4.23 nM, roughly five times lower affinity than native GLP-1, and a cAMP EC50 of 0.934 nM. In the same assays GLP-S bound the GLP-1 receptor at 1.97 nM with a cAMP EC50 of 0.0571 nM.[1]

Figure 2. GLP-TZ potency at the GIP and GLP-1 receptors.

Horizontal bar chart on a log scale comparing cAMP EC50 and binding Ki in nanomolar for GLP-TZ at the GIP receptor, GLP-TZ at the GLP-1 receptor and GLP-S at the GLP-1 receptor.

In HEK293 cells expressing the human receptors, GLP-TZ is far more potent at the GIP receptor than at the GLP-1 receptor on both binding and cAMP readouts. Values are in vitro only and are not interchangeable with other assay systems.[1]

Measuring Gs activation directly gives the same picture. GLP-TZ was a full agonist at the GIP receptor (EC50 0.379 nM against 1.43 nM for GIP) but only a partial agonist at the GLP-1 receptor, reaching 51% of the maximum GLP-1 effect (EC50 0.617 nM against 1.63 nM for GLP-1).[2]

The imbalance continues past the G protein. At the GLP-1 receptor, GLP-TZ recruited beta-arrestin2 so weakly that a potency value could not be assigned, staying under 10% of the maximum GLP-1 effect, and it internalised the receptor far less than GLP-1 did (43.6% of maximal internalisation, EC50 101.9 nM against 22.2 nM). At the GIP receptor it recruited beta-arrestin2 as a full agonist (EC50 2.34 nM against 1.58 nM for GIP) and internalised the receptor to the same extent as GIP (EC50 18.1 nM against 18.2 nM). In isolated mouse islets, beta-arrestin1 limited the insulin response to GLP-1 but not the response to GIP or to GLP-TZ, which is the authors' explanation for why weak arrestin coupling at the GLP-1 receptor may help rather than hinder.[2]

What did GLP-TZ do in animal studies?

In obese mice it lowered food intake and body weight, and it left them more sensitive to insulin than weight loss alone accounts for.

In diet-induced obese mice starting at roughly 45 g, chronic dosing produced a dose-dependent fall in body weight that was greater than the fall produced by GLP-S, and the loss came mainly from fat rather than lean tissue. Food intake fell more steeply and stayed down longer over the first 7 to 10 days, and energy expenditure rose slightly from day 7 onwards, an increase not seen with GLP-S in the same experiment.[1]

The sharpest result comes from a clamp study. Obese mice were dosed once daily for 14 days and then measured with a hyperinsulinaemic-euglycaemic clamp, the standard way to quantify insulin sensitivity. GLP-TZ at 3 nmol/kg and GLP-S at 10 nmol/kg produced the same weight loss, yet the glucose infusion rate rose 4.7-fold against vehicle for GLP-TZ and 3.5-fold for GLP-S. A pair-fed group, eating exactly as much as the GLP-TZ group but given no compound, reached 3.0-fold. The authors attribute roughly 30% of the GLP-TZ effect to something other than weight loss.[3]

Figure 3. What GLP-TZ did in obese mice after 14 days.

Bar chart of clamp glucose infusion rate as fold change against vehicle in obese mice: vehicle 1.0x, pair-fed 3.0x, GLP-S 3.5x and GLP-TZ 4.7x at matched weight loss; and in a second panel GLP-TZ 5.2x in wild-type mice, 1.7x in GLP-1 receptor knockout mice with no weight change, and 1.7x for a selective GIP receptor agonist.

Clamp glucose infusion rate after 14 days of once-daily dosing in obese mice, as fold change against vehicle. At matched weight loss GLP-TZ reached 4.7-fold against 3.5-fold for GLP-S, with a pair-fed group at 3.0-fold. Removing the GLP-1 receptor left a 1.7-fold rise with no change in weight or food intake.[3]

Two further experiments pin that extra component on the GIP arm. In mice lacking the GLP-1 receptor entirely, fed a 60% fat diet for 12 weeks until they weighed over 50 g, GLP-TZ changed neither body weight nor food intake, yet still raised the glucose infusion rate 1.7-fold. A selective long-acting GIP receptor agonist given to wild-type obese mice reproduced the same 1.7-fold rise while lowering body weight by only about 4%. Both treatments lowered circulating branched-chain amino acids and raised catabolic gene expression in brown adipose tissue, while endogenous glucose production did not shift in any group, which places the effect in peripheral tissue rather than liver.[3]

Feeding behaviour shifted as well as fell. In mice offered a choice between a low-fat and a high-fat diet, GLP-TZ moved intake towards the low-fat option and away from the high-fat one, and it also reduced intake of nutritive tastants (fructose, sucrose) and of a non-nutritive one (sucralose). Meal pattern analysis across 14 days showed smaller and less frequent meals.[4]

GLP-TZ, GLP-S and GLP-RT: which receptors each one targets

The three NextGenPeps incretin research compounds differ in how many receptors each molecule engages. The list below states receptor targets and chemical class only. It is not a comparison of how well any of them performs.

  • GLP-S. Class: GLP-1 receptor agonist. Receptor targets: GLP-1 receptor only.

  • GLP-TZ. Class: dual incretin receptor agonist. Receptor targets: GLP-1 receptor and GIP receptor.

  • GLP-RT. Class: triple receptor agonist. Receptor targets: GLP-1 receptor, GIP receptor and glucagon receptor.

Each is supplied as a separate research material. Choosing between them is a question of which receptors an experiment needs to engage.

What is GLP-TZ made of?

A 39-residue synthetic peptide with a fatty acid chain attached partway along it. The backbone carries two copies of a non-coded amino acid, alpha-aminoisobutyric acid (Aib), at positions 2 and 13. Aib at position 2 is the standard way to block dipeptidyl peptidase-4, the enzyme that clips the first two residues off native incretins within minutes. The lysine at position 20 carries a C20 fatty diacid attached through a linker, and the C-terminus is amidated.[1]

The fatty diacid governs how long the molecule persists. It binds reversibly to serum albumin, which keeps the peptide in circulation and slows renal clearance. The practical consequence in assay work is a large albumin shift: adding 1% human serum albumin moved apparent potency 26-fold at the GIP receptor and 81-fold at the GLP-1 receptor, while the native hormones were unaffected. Assay buffers differing in albumin content will therefore return different numbers.[2]

The published sequence begins Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr. The molecular formula is C225H348N48O68 and the molecular weight is 4813.5 g/mol, with a monoisotopic mass of 4810.52 Da.[1]

GLP-TZ at a glance

  • Compound: GLP-TZ, a synthetic dual incretin receptor agonist peptide

  • Class: Lipidated 39-residue peptide; agonist at the GIP receptor and the GLP-1 receptor

  • Structure: 39 residues with Aib at positions 2 and 13, a C20 fatty diacid on the lysine at position 20, and an amidated C-terminus[1]

  • Molecular formula: C225H348N48O68

  • Molecular weight: 4813.5 g/mol; monoisotopic mass 4810.52 Da

  • Strength: 10 mg or 20 mg per vial, depending on the variant selected

  • Identity and purity: Identity by LC-MS/MS and purity by RP-HPLC at 214 nm; 99.76% on the current 10 mg lot (independent lab, September 25, 2026). The certificate is published in the NextGenPeps COA library

  • Endotoxin: Under 0.05 EU/ml on the current 10 mg lot, tested per USP <85>

  • Appearance: White lyophilised powder, sealed vial

  • Reconstitution: Sterile or bacteriostatic water

  • Receptor potency: GIP receptor Ki 0.135 nM, cAMP EC50 0.0224 nM; GLP-1 receptor Ki 4.23 nM, cAMP EC50 0.934 nM (human receptors in HEK293 cells)[1]

  • Regulatory status: Research use only. Not an approved drug, supplement or diagnostic

Is GLP-TZ FDA approved?

No. GLP-TZ is not an approved drug, not a supplement and not a diagnostic, and it has no approved use of any kind. It is supplied as a research material for in vitro work and approved animal studies. Research-grade material is not manufactured to the potency and sterility standards applied to pharmaceutical products, so quantitative work should calibrate against its own reference.

What is GLP-TZ used to study?

GLP-TZ is reached for when an experiment needs both incretin receptors engaged by one molecule, or when the question is what the GIP arm contributes. Each field below leans on a different property.

  • Dual incretin receptor pharmacology. Binding, cAMP, Gs activation and arrestin assays at the two receptors side by side, with native GIP and GLP-1 as reference agonists.[1,2]

  • Biased and imbalanced agonism. One ligand that is balanced at one receptor and strongly cAMP-biased at another is a clean model system for studying signalling bias.[2]

  • Adipose tissue and insulin sensitivity. Clamp studies, tissue glucose uptake and branched-chain amino acid measurements in rodent models of diet-induced obesity.[3]

  • Feeding behaviour and macronutrient choice. Two-choice diet paradigms, tastant intake and meal pattern analysis in mice.[4]

  • Assay design. The large albumin shift makes it a useful test case for how protein binding distorts apparent potency.[2]

Buying GLP-TZ for research: what each vial includes

GLP-TZ is supplied as lyophilised powder in a sealed, labelled vial, in a 10 mg or a 20 mg strength. The current 10 mg lot was analysed by an independent laboratory on September 25, 2026: identity by LC-MS/MS, purity by RP-HPLC at 214 nm, content by HPLC quantitation, and endotoxin per USP <85>. Purity was 99.76% and endotoxin came in under 0.05 EU/ml. Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library.

  • Verified identity, purity and endotoxin. 99.76% purity and under 0.05 EU/ml endotoxin on the current 10 mg lot, with the certificate published in the COA library. The 20 mg vial has no certificate of its own published yet; refer to the COA library for the lot shipped.

  • Two strengths. 10 mg per vial or 20 mg per vial, selected at the variant level.

  • US-based fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.

  • Research use only. GLP-TZ is sold strictly for in vitro and approved animal research. It is not for human or veterinary use and is not sold as a drug, supplement or diagnostic.

GLP-TZ handling, storage and analytical notes

Format. Supplied as lyophilised powder in a sealed vial and reconstituted with sterile or bacteriostatic water. No dosing instructions are supplied, and none should be inferred from the studies above.

Storage. Keep the sealed vial cold (2 to 8 °C, or −20 °C for longer holding) and protected from light. After reconstitution, hold the solution at 2 to 8 °C and avoid repeated freeze-thaw cycles.

Albumin in assays. Because the C20 diacid binds albumin, apparent potency depends heavily on the protein content of the buffer: a 26-fold shift at the GIP receptor and an 81-fold shift at the GLP-1 receptor were recorded on adding 1% human serum albumin. Report the albumin concentration alongside any EC50 value.[2]

Analytical. Identity is confirmed by LC-MS/MS against the expected mass of 4810.52 Da monoisotopic, and purity by RP-HPLC at 214 nm. Lipidated peptides can show tailing and carryover on reversed-phase columns, so blank injections between runs are worth including.

Naming. GLP-TZ is the NextGenPeps catalogue code for this dual incretin receptor agonist. GIP and GLP-1 on this page mean the native hormones, not catalogue products. GLP-S and GLP-RT are separate NextGenPeps research materials with different receptor targets.

What is not established about GLP-TZ

  • Which cells the GIP arm acts on. The weight-independent insulin sensitisation is attributed to white adipose tissue, but GIP receptor expression there sits mainly in pericytes and mesothelial cells rather than in adipocytes, so the responsible cell type is unsettled.[5] Inducing the GIP receptor in adipocytes alone was enough to drive large weight loss in mice through futile calcium cycling, which argues the tissue matters even where the cell type does not fit.[7]

  • How far rodent results carry. Every quantitative result on this page comes from mice or from cells expressing human receptors. Species differences in incretin receptor pharmacology are well documented, and findings do not transfer automatically.[6]

  • Whether GIP receptor agonism or antagonism is the better strategy. Both directions have produced metabolic benefit in animal models and the field has not resolved why.[6]

  • Assay-dependent numbers. Potency values move by one to two orders of magnitude with albumin content, so figures from different laboratories are not directly comparable.[2]


Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.

Published research

Compound information

Molecular Class
Lipidated synthetic 39-residue peptide; dual incretin receptor agonist
Receptors
GIP receptor (GIPR) and GLP-1 receptor (GLP-1R)
Structure
39 residues with Aib at positions 2 and 13, a C20 fatty diacid on the lysine at position 20, and an amidated C-terminus
Sequence (N-terminal segment)
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr...
Molecular Formula
C225H348N48O68
Molecular Weight
4813.5 g/mol; monoisotopic mass 4810.52 Da
Strength
10 mg or 20 mg per vial
Physical Form
White lyophilised powder, sealed vial
Purity
99.76% by RP-HPLC at 214 nm on the current 10 mg lot (independent lab, Sep 25, 2026); identity by LC-MS/MS
Endotoxin
Under 0.05 EU/ml on the current 10 mg lot, per USP <85>
Receptor potency
GIPR Ki 0.135 nM, cAMP EC50 0.0224 nM; GLP-1R Ki 4.23 nM, cAMP EC50 0.934 nM (human receptors, HEK293)
Regulatory status
Research use only. Not an approved drug, supplement or diagnostic

Storage & stability

  • Lyophilised powder in a sealed vial
  • Store cold, protected from light and moisture
  • Avoid repeated freeze-thaw cycles after reconstitution
  • Report assay buffer albumin content alongside any potency value, because the C20 diacid binds albumin
Lyophilised
2 to 8 °C, or −20 °C for longer holding, in the sealed vial
Reconstituted
2 to 8 °C, protected from light
Reconstitute with
Sterile or bacteriostatic water
Shipping
Ships within 24 hours from the United States

Cited literature

  1. 01
    LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

    Coskun T, Sloop KW, Loghin C, et al. · Mol Metab 2018 · PubMed · DOI · Free full text

    Describes the molecule (39 residues, Aib at 2 and 13, C20 diacid on Lys20, amidated C-terminus) and reports receptor binding and cAMP potency at both receptors, plus greater body weight and food intake reduction than a GLP-1 receptor agonist in diet-induced obese mice. The rodent body weight data are shown graphically, so no percentage figures are stated in the text.

  2. 02
    Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

    Willard FS, Douros JD, Gabe MBN, et al. · JCI Insight 2020 · PubMed · DOI · Free full text

    Full agonism and balanced arrestin coupling at the GIP receptor, against weak arrestin recruitment, partial Gs agonism and reduced internalisation at the GLP-1 receptor. Also quantifies the albumin shift. In vitro work plus isolated mouse islets only.

  3. 03
    GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

    Samms RJ, Christe ME, Collins KAL, et al. · J Clin Invest 2021 · PubMed · DOI · Free full text

    Clamp studies in obese mice: glucose infusion rate rose 4.7-fold against 3.5-fold for a GLP-1 receptor agonist at matched weight loss, and 1.7-fold in GLP-1 receptor knockout mice with no weight change. The weight-independent share is an estimate, and the n values quoted in the figure legend and the methods differ for the knockout experiment.

  4. 04
    142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding

    Cosgrove R, Antonellis MP, Droz B, et al. · Diabetes 2020 · DOI

    Mouse feeding study: dose-dependent falls in body weight and food intake over 14 days from smaller and less frequent meals, a shift in two-choice diet preference towards low-fat food, and reduced tastant intake. A conference abstract, so it has not been through full peer review and reports no numeric values.

  5. 05
    GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue

    Campbell JE, Beaudry JL, Svendsen B, et al. · Diabetes 2022 · PubMed · DOI

    Mouse genetics and single-nucleus RNA sequencing place GIP receptor expression in white adipose tissue mainly in pericytes and mesothelial cells rather than adipocytes. Complicates adipocyte-centred explanations of GIP receptor agonism, though it does not test any dual agonist.

  6. 06
    Glucose-dependent insulinotropic polypeptide (GIP)

    Müller TD, Adriaenssens A, Ahrén B, et al. · Mol Metab 2025 · DOI · Free full text

    Multi-author review of GIP biology covering receptor pharmacology, tissue distribution and the unresolved question of whether GIP receptor agonism or antagonism is the more useful direction. A narrative review, not a primary data source.

  7. 07
    The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice

    Yu X, Chen S, Funcke JB, et al. · Cell Metab 2025 · PubMed · DOI

    Inducing the GIP receptor only in mouse adipocytes protected against diet-induced obesity and drove substantial weight loss through SERCA-mediated futile calcium cycling. A transgenic overexpression model, so it shows what adipocyte GIP receptor signalling can do rather than what a dual agonist does.

  8. 08
    Semaglutide lowers body weight in rodents via distributed neural pathways

    Gabery S, Salinas CG, Paulsen SJ, et al. · JCI Insight 2020 · DOI · Free full text

    Maps where a GLP-1 receptor agonist acts in mice and rats: circumventricular organs and nearby hindbrain and hypothalamic nuclei, with no general blood-brain barrier crossing. Characterises the GLP-1 arm in rodents; it does not test a dual agonist.

Frequently asked questions

How is GLP-TZ packaged?

GLP-TZ is supplied in the product format and quantity shown for the selected variant. Please inspect the sealed package when it arrives and contact support promptly if the package or labeling appears damaged.

How is GLP-TZ shipped?

Orders are shipped within the United States via USPS. Transit times are typically 3–7 business days, depending on destination and carrier conditions. Tracking information is provided when available.

How should GLP-TZ be stored?

Storage requirements are product-specific. Keep GLP-TZ in its original labeled container and follow the product documentation or manufacturer instructions supplied with the order. Contact support if the applicable storage guidance is not available.

What is the refund policy for GLP-TZ?

Due to the nature of research materials, NextGenPeps orders are final and are not eligible for refunds, returns, or exchanges. Review the shipping and reship policies before ordering.

Is GLP-TZ intended for human use?

No. NextGenPeps materials are supplied strictly for laboratory research and development use and are not intended for human or animal consumption, clinical use, diagnostic use, cosmetic use, or dietary use.

Customer reviews

4.7out of 5 · 3 reviews

Wide selection

There's a great selection of glps on here, it’s basically a one stop shop for anything you need

Daniella N.

Great for Laboratory Use

NextGenPeps is our lab's official supplier for all research peptides. No impurities in solutions and results are reproducible over different lots.

Sawyer D.

Cares about their customers

I got a free bac water with my replacement, really appreciated the gesture from these guys <3

Evie O.

Common research questions

What is GLP-TZ?

GLP-TZ is a synthetic 39-residue peptide that acts as an agonist at two incretin receptors at once, the GIP receptor and the GLP-1 receptor. It is used in laboratory work as a single-molecule tool for asking what GIP receptor activation adds on top of GLP-1 receptor activation, a question that is awkward to address when two separate agonists are given together. Its backbone carries alpha-aminoisobutyric acid at positions 2 and 13 and a C20 fatty diacid on the lysine at position 20. NextGenPeps supplies it as lyophilised powder in 10 mg and 20 mg research vials, for in vitro work and approved animal studies only.

How does GLP-TZ work?

Both the GIP receptor and the GLP-1 receptor are class B G-protein-coupled receptors that couple to Gs, so agonist binding raises intracellular cAMP. In pancreatic beta cells that rise amplifies insulin release when glucose is already elevated, which is why incretin signalling is described as glucose-dependent. GLP-TZ engages the two receptors unevenly: in cells expressing the human receptors it bound the GIP receptor with a Ki of 0.135 nM and the GLP-1 receptor with a Ki of 4.23 nM, about five times weaker than native GLP-1. At the GLP-1 receptor it also favours cAMP over beta-arrestin recruitment and causes much less receptor internalisation than GLP-1 does.

What is the difference between GLP-TZ and GLP-S?

The difference is which receptors each molecule engages. GLP-S is a GLP-1 receptor agonist and targets that receptor alone. GLP-TZ is a dual incretin receptor agonist and targets both the GLP-1 receptor and the GIP receptor. A third NextGenPeps research compound, GLP-RT, adds the glucagon receptor to those two. In cell assays the two differ at the shared receptor as well: GLP-S bound the GLP-1 receptor with a Ki of 1.97 nM and a cAMP EC50 of 0.0571 nM, while GLP-TZ was weaker on both readouts. Which compound suits an experiment is a question of which receptors it needs to engage.

What is GLP-TZ made of?

GLP-TZ is a linear 39-residue peptide. Two positions, 2 and 13, carry alpha-aminoisobutyric acid, a non-coded amino acid; the substitution at position 2 blocks dipeptidyl peptidase-4, the enzyme that otherwise clips the first two residues off native incretins within minutes. The lysine at position 20 carries a C20 fatty diacid attached through a linker, and the C-terminus is amidated. The published sequence begins Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr. The molecular formula is C225H348N48O68 and the molecular weight is 4813.5 g/mol, with a monoisotopic mass of 4810.52 Da.

What has GLP-TZ done in animal studies?

In diet-induced obese mice starting at roughly 45 g, chronic dosing lowered body weight in a dose-dependent way, mainly through fat loss, and reduced food intake more steeply and for longer than a GLP-1 receptor agonist over the first 7 to 10 days. In a clamp study in obese mice dosed once daily for 14 days, the glucose infusion rate rose 4.7-fold against vehicle for GLP-TZ and 3.5-fold for a GLP-1 receptor agonist at matched weight loss, with a pair-fed group at 3.0-fold. In mice lacking the GLP-1 receptor, GLP-TZ changed neither weight nor food intake but still raised the glucose infusion rate 1.7-fold, which the authors attribute to the GIP arm.

How should GLP-TZ be stored and handled in the laboratory?

Keep the sealed vial of lyophilised powder cold, at 2 to 8 degrees Celsius, or at minus 20 degrees Celsius for longer holding, protected from light and moisture. Reconstitute with sterile or bacteriostatic water, then hold the solution at 2 to 8 degrees Celsius and avoid repeated freeze-thaw cycles. One analytical point is worth planning around: the C20 fatty diacid binds serum albumin, and adding 1% human serum albumin shifted apparent potency 26-fold at the GIP receptor and 81-fold at the GLP-1 receptor, so the albumin content of an assay buffer should be reported alongside any potency value.

Frequently Researched with

GLP-RT

✓ 99.72% purity

GLP-RT

$89.00$71.00

GHK-Cu

✓ 99.73% purity

GHK-Cu

$74.00$59.00

GLOW

✓ 99.71% purity

GLOW

$134.00$107.00

BPC-157

✓ 99.748% purity

BPC-157

$46.00$37.00

You have an unfinished subscription checkout

Continue your saved checkout, or replace its item with . Your saved selection and existing subscriptions will stay unchanged.

Continue saved checkout
NextGenPeps

Reliable and innovative research with our top-grade research materials and novel research compounds tailored to lead the competitive research industry. Choose research quality. Choose NextGenPeps.

Customer Service: +1 (971) 300-1435

Get 10% Off Your First Order

Sign up now and receive a 10% discount code valid on your next purchase!

Nextgenpeps LLC

The statements made within this website have not been evaluated by the US Food and Drug Administration. The materials offered by this company are not intended to diagnose, treat, cure, or prevent any disease. All research materials on this site are for laboratory research and development use only, and are not intended for human use.

NextGenPeps is a chemical supplier. NextGenPeps is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. NextGenPeps is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.

Privacy PolicyTerms & ConditionsAffiliate Program

501 W Broadway Ste A, San Diego, CA 92101

© 2026 NextGenPeps. All rights reserved.

Visa
American Express
Mastercard
PayPal
Discover
Apple Pay